Last reviewed · How we verify

NCT03296046: LPLB

Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL)

Completed Last updated 28 September 2017
What this trial tests

trial testing Blood test in Persistent Polyclonal B-Cell Lymphocytosis in 100 participants. Completed in 31 December 2015.

Timeline
13 November 2012
Primary endpoint
31 December 2015
31 December 2015

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date13 November 2012
Primary completion31 December 2015
Estimated completion31 December 2015
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Persistent Polyclonal B-Cell Lymphocytosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is the description of all French cases of PPBL and the establishment of minimal criteria for the pathology diagnosis and its follow-up. The secondary objective is the immunologic and genetic characterization of lymphoid cells causing the disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood test

Trials testing the same drug.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03296046.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing